154 related articles for article (PubMed ID: 1497648)
41. Intrarenal conversion of big endothelin-1 to endothelin-1 in the rat.
Fujita K; Matsumura Y; Kita S; Hisaki K; Takaoka M; Morimoto S
Life Sci; 1994; 55(16):1285-91. PubMed ID: 7934630
[TBL] [Abstract][Full Text] [Related]
42. Evidence for metalloprotease involvement in the in vivo effects of big endothelin 1.
Pollock DM; Opgenorth TJ
Am J Physiol; 1991 Jul; 261(1 Pt 2):R257-63. PubMed ID: 1650147
[TBL] [Abstract][Full Text] [Related]
43. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
[TBL] [Abstract][Full Text] [Related]
44. Differential pharmacological profile of endothelin-1 and its precursor, big endothelin.
Le Monnier de Gouville AC; Cavero I
J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S362-5. PubMed ID: 1725381
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the cardiovascular and neural activity of endothelin-1, -2, -3 and respective proendothelins: effects of phosphoramidon and thiorphan.
Mattera GG; Eglezos A; Renzetti AR; Mizrahi J
Br J Pharmacol; 1993 Sep; 110(1):331-7. PubMed ID: 8106108
[TBL] [Abstract][Full Text] [Related]
46. Phosphoramidon does not inhibit endogenous endothelin-1 release stimulated by hemorrhage, cytokines and hypoxia in rats.
Vemulapalli S; Chiu PJ; Griscti K; Brown A; Kurowski S; Sybertz EJ
Eur J Pharmacol; 1994 May; 257(1-2):95-102. PubMed ID: 8082712
[TBL] [Abstract][Full Text] [Related]
47. Effect of phosphoramidon on big endothelin-2 conversion into endothelin-2 in human renal adenocarcinoma (ACHN) cells. Analysis of endothelin-2 biosynthetic pathway.
Yorimitsu K; Shinmi O; Nishiyama M; Moroi K; Sugita Y; Saito T; Inagaki Y; Masaki T; Kimura S
FEBS Lett; 1992 Dec; 314(3):395-8. PubMed ID: 1468574
[TBL] [Abstract][Full Text] [Related]
48. Human breast cancer cells contain a phosphoramidon-sensitive metalloproteinase which can process exogenous big endothelin-1 to endothelin-1: a proposed mitogen for human breast fibroblasts.
Patel KV; Schrey MP
Br J Cancer; 1995 Mar; 71(3):442-7. PubMed ID: 7880721
[TBL] [Abstract][Full Text] [Related]
49. Characterization of endothelin converting enzyme from intact cells of a permanent human endothelial cell line, EA.hy926.
Ahn K; Pan SM; Zientek MA; Guy PM; Sisneros AM
Biochem Mol Biol Int; 1996 Jun; 39(3):573-80. PubMed ID: 8828809
[TBL] [Abstract][Full Text] [Related]
50. Radioimmunoassay evidence that the pressor effect of big endothelin-1 is due to local conversion to endothelin-1.
Corder R; Vane JR
Biochem Pharmacol; 1995 Jan; 49(3):375-80. PubMed ID: 7857324
[TBL] [Abstract][Full Text] [Related]
51. Endothelin-converting enzyme: substrate specificity and inhibition by novel analogs of phosphoramidon.
Keller PM; Lee CP; Fenwick AE; Atkinson ST; Elliott JD; DeWolf WE
Biochem Biophys Res Commun; 1996 Jun; 223(2):372-8. PubMed ID: 8670289
[TBL] [Abstract][Full Text] [Related]
52. Importance of the C-terminal region of big endothelin-1 for specific conversion by phosphoramidon-sensitive endothelin converting enzyme.
Okada K; Takada J; Arai Y; Matsuyama K; Yano M
Biochem Biophys Res Commun; 1991 Oct; 180(2):1019-23. PubMed ID: 1953706
[TBL] [Abstract][Full Text] [Related]
53. Conversion of big endothelin isopeptides to mature endothelin isopeptides by cultured bovine endothelial cells.
Ohnaka K; Takayanagi R; Ohashi M; Nawata H
J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S17-9. PubMed ID: 1725321
[TBL] [Abstract][Full Text] [Related]
54. Endothelium-independent pressor effect of big endothelin-1 and its inhibition by phosphoramidon in rat mesenteric artery.
Hisaki K; Matsumura Y; Nishiguchi S; Fujita K; Takaoka M; Morimoto S
Eur J Pharmacol; 1993 Sep; 241(1):75-81. PubMed ID: 8223929
[TBL] [Abstract][Full Text] [Related]
55. Phosphoramidon, an endothelin converting enzyme inhibitor attenuates local gastric ischemia-reperfusion injury in rats.
Hassan M; Kashimura H; Matsumaru K; Nakahara A; Fukutomi H; Muto H; Goto K; Tanaka N
Life Sci; 1997; 61(10):PL 141-7. PubMed ID: 9296343
[TBL] [Abstract][Full Text] [Related]
56. Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme.
Ikegawa R; Matsumura Y; Tsukahara Y; Takaoka M; Morimoto S
Biochem Biophys Res Commun; 1990 Sep; 171(2):669-75. PubMed ID: 2206130
[TBL] [Abstract][Full Text] [Related]
57. [D-Val22]big ET-1[16-38] inhibits endothelin-converting enzyme activity: a promising concept in the prevention of cerebral vasospasm.
Zimmermann M; Jung CS; Vatter H; Raabe A; Seifert V
Neurosurg Rev; 2003 May; 26(2):125-32. PubMed ID: 12962299
[TBL] [Abstract][Full Text] [Related]
58. [Phe22]-big endothelin-1[19-37]: a new and potent inhibitor of the endothelin-converting enzyme.
Claing A; Neugebauer W; Yano M; Rae GA; D'Orléans-Juste P
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S72-4. PubMed ID: 8587472
[TBL] [Abstract][Full Text] [Related]
59. Attenuation of ischemic acute renal failure by phosphoramidon in rats.
Vemulapalli S; Chiu PJ; Chintala M; Bernardino V
Pharmacology; 1993 Sep; 47(3):188-93. PubMed ID: 8415869
[TBL] [Abstract][Full Text] [Related]
60. Synthesis of a phostone glycomimetic of the endothelin converting enzyme inhibitor phosphoramidon.
Hanessian S; Rogel O
Bioorg Med Chem Lett; 1999 Aug; 9(16):2441-6. PubMed ID: 10476884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
